HOME >> MEDICINE >> NEWS
Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence

San Antonio, December 8 Pfizer announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for AROMASIN (exemestane tablets) in the adjuvant treatment of postmenopausal women with estrogen receptor positive or receptor unknown early-stage breast cancer.

AROMASIN is a hormonal therapy that belongs to a class of drugs called aromatase inhibitors which work by blocking the production of estrogen, which is known to play a key role in the development and growth of breast cancer. For many years, treatment with tamoxifen has been the standard hormonal therapy for postmenopausal women with breast cancer that is dependent upon estrogen for growth. Results from the pivotal Intergroup Exemestane Study (IES), published in the New England Journal of Medicine, demonstrated that postmenopausal breast cancer patients who had been treated with 2-3 years of tamoxifen for early breast cancer (adjuvant treatment with tamoxifen) and were switched to AROMASIN significantly reduced their risk of recurrence and increased disease-free survival compared to patients who remained on tamoxifen for the entire five years.

"The adjuvant approval of AROMASIN would provide oncologists with a treatment regimen that significantly reduces the recurrence of breast cancer," said Dr. Stephen Jones, medical director at U.S. Oncology Research. "This filing is an important step toward providing postmenopausal women with a critical treatment option that can significantly improve survival of early breast cancer when compared to tamoxifen."

Pfizer's announcement closely follows newly released American Society of Clinical Oncology (ASCO) recommendations on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer and coincides with the presentation of an update on the study trial being used to support the filing. The ASCO recommendations,
'"/>

Contact: Steven Cooper
steven.cooper@edelman.com
917-301-7566
Edelman Public Relations
8-Dec-2004


Page: 1 2 3

Related medicine news :

1. Updated press release to October 2004 Cochrane Review
2. Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
6. Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds
7. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
8. Study supports tailoring adjuvant therapy for early-stage breast cancer
9. Nordic collaboration gives new insights into adjuvant chemotherapy
10. New tipifarnib (R115777) data in AML presented at American Society of Hematology Annual Meeting
11. Elderly cancer patients are significantly under-represented in cancer clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... Dr. Christine Blaine ... cosmetic surgeons, with medical offices located in Staten Island, Huntington and NYC, NY. ... a beautifully designed medical suite at The Parlor NYC at 160 Madison Avenue. ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... cannabis and botanically-derived terpenes, has officially released its new terpene infused product ... a way for consumers to enjoy cannabis terpene profiles and flavors worldwide. , ...
(Date:6/28/2020)... ... , ... Medisend College of Biomedical Engineering Technology, a Dallas-based ... prepares graduates for professional careers as field service engineers and biomedical equipment technicians, ... Ms. Williams currently serves as Associate Vice Chancellor of Workforce and Community Initiatives ...
(Date:6/28/2020)... ... 27, 2020 , ... The FSHD Society announced the opening ... the organization’s history. The online conference takes the place of FSHD Connect, the ... year due to COVID-19. Nearly 300 individuals and families living with FSHD are ...
(Date:6/24/2020)... ... June 24, 2020 , ... At Allerio we have chosen to do things ... communications. We knew it had to be portable, it had to be reliable, it ... to work. , We are proud to announce that Allerio has passed all FCC ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... ... July 02, 2020 , ... Realty ONE Group ... health series on its live agent Town Halls, furthering its commitment to its ... series includes special guests and Realty ONE Group leadership discussing social, mental, physical ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... time ever, Stratodesk NoTouch OS is available on NComputing devices. Thanks to fantastic ... NComputing and Stratodesk have formed a new partnership that will make the full ...
(Date:6/25/2020)... ... 2020 , ... Billon Group received a £50,000 grant in ... to store COVID-19 related certificates to support workers’ safe return to the workplace. ... publishing, sharing and verifying a wide array of workplace training or medical test ...
Breaking Medicine Technology:
Cached News: